New gene therapy targets tough cancers in early trial

NCT ID NCT07596693

Recruiting now Disease control Sponsor: TCRx Therapeutics Co.Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is to check safety and find the right dose, with 30 participants expected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KXV01 TCR Lentinvivo injection (a personalized gene therapy that trains immune cells to attack tumors)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The therapy may cause serious side effects like cytokine release syndrome, and it may not shrink tumors or extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University
RECRUITING

Shanghai, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.